Eisai to Develop Belviq for Japan Market via Expanded Deal with Arena

Eisai has expanded its licensing agreement with US biotech Arena Pharmaceuticals Inc. for lorcaserin, an antiobesity agent that went on sale in the US under the brand name of Belviq in June, opening the way for the drug’s development for...read more